Monteris Medical Company Profile

Background

Overview

Monteris Medical is a privately held medical device company specializing in minimally invasive neurosurgical technologies. Founded in 1999, the company is headquartered in Minnetonka, Minnesota, USA, with an additional office in Winnipeg, Manitoba, Canada. Monteris Medical's primary focus is on developing and commercializing MRI-guided laser ablation systems for the treatment of neurological diseases, including brain tumors, radiation necrosis, and drug-resistant epilepsy. The company's flagship product, the NeuroBlate® System, offers a minimally invasive alternative to traditional brain surgery, enabling precise ablation of brain lesions with reduced risk and recovery time.

Mission and Vision

Mission: To be the leader in image-guided thermal therapy, providing proven, intuitive, and integrated solutions that deliver value to partners in the treatment of epilepsy and brain cancer.

Vision: To offer hope and healing to patients worldwide as the partner of choice in delivering transformational neurological solutions.

Industry Significance

Monteris Medical has established itself as a leader in the field of minimally invasive neurosurgery. The NeuroBlate® System is the only MRI-guided laser ablation system with a robotic interface, supported by a robust foundation of prospective multi-center clinical evidence. This technology has revolutionized the approach to treating brain tumors and other neurological conditions, offering patients a less invasive option with improved outcomes.

Key Strategic Focus

Core Objectives

Expand the adoption of the NeuroBlate® System across North America and internationally.

Advance clinical research to further validate the efficacy and safety of laser interstitial thermal therapy (LITT) for various neurological conditions.

Innovate and enhance the NeuroBlate® System to incorporate the latest technological advancements.

Areas of Specialization

Minimally invasive neurosurgical procedures.

MRI-guided laser ablation therapy.

Treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy.

Key Technologies Utilized

MRI-guided laser interstitial thermal therapy (LITT).

Robotic control systems for precise laser delivery.

Real-time MRI thermometry for monitoring ablation zones.

Primary Markets Targeted

Neurosurgical centers and hospitals.

Medical institutions specializing in oncology and neurology.

Patients with brain tumors, radiation necrosis, and drug-resistant epilepsy.

Financials and Funding

Total Funds Raised

Monteris Medical has secured approximately $143.1 million in funding over multiple rounds.

Recent Funding Rounds

October 2022: Secured $73 million in combined equity and debt financing. The equity financing was led by InnovaHealth Partners and supported by Birchview Capital, while the debt facility was provided by Madryn Asset Management, LP.

March 2026: Closed $28 million in Series E equity financing, with participation from existing investors InnovaHealth Partners and Birchview Capital, as well as new investors including OSF Ventures and the Colorado University Healthcare Innovation Fund.

Utilization of Capital

The funds have been allocated to:

Accelerate market adoption of the NeuroBlate® System.

Support ongoing clinical research and technology development.

Expand the company's commercial footprint in the U.S. and internationally.

Pipeline Development

Key Pipeline Candidates

NeuroBlate® System: The primary product, currently in use across more than 100 hospitals in the U.S. and Canada, is continually being refined and enhanced.

Stages of Development

The NeuroBlate® System is fully developed and commercially available.

Target Conditions

Primary and metastatic brain tumors.

Radiation necrosis.

Drug-resistant epilepsy.

Anticipated Milestones

Ongoing clinical studies to further validate the efficacy of the NeuroBlate® System.

Expansion into new international markets.

Technological Platform and Innovation

Proprietary Technologies

NeuroBlate® System: An MRI-guided laser ablation system with a robotic interface for precise and safe delivery of laser energy to brain lesions.

Significant Scientific Methods

MRI-guided laser interstitial thermal therapy (LITT).

Real-time MRI thermometry for monitoring ablation zones.

Robotic control systems for accurate laser delivery.

Leadership Team

Key Executives

Martin J. Emerson: President and CEO.

Eric Andrews: Vice President of Engineering.

Jared Hayman: Vice President of North American Sales.

Jennifer Englund: Senior Vice President of Global Clinical Affairs.

Susan Allen: Vice President of Human Resources.

Doug Pahr: Controller.

Richard Tyc: Vice President of Technology and Advanced Development.

Laura Menck: Senior Director of Clinical Operations and Clinical Quality.

Andrew O'Connor: Field Development Director.

Emily Smith: Senior Director of Marketing.

Leadership Changes

No significant leadership changes have been reported in recent years.

Market and Competitor Overview

Market Insights and Dynamics

The market for minimally invasive neurosurgical technologies is growing, driven by the demand for less invasive procedures with shorter recovery times and improved patient outcomes. Key trends include the adoption of MRI-guided therapies and robotic-assisted surgeries.

Competitor Analysis

EDAP TMS: Develops minimally invasive medical devices for urology.

XACT Robotics: Provides radiology and robotics technology solutions for patient diagnosis and treatment.

Perfint Healthcare: Offers image-guided therapy products.

Ambu Innovation: Specializes in medical devices for minimally invasive procedures.

Strategic Collaborations and Partnerships

OSF Ventures: Participated in the March 2026 funding round, reflecting confidence in Monteris Medical's technology and mission.

Colorado University Healthcare Innovation Fund: Also participated in the March 2026 funding round, indicating strong support from healthcare institutions.

Operational Insights

Monteris Medical's strategic focus on minimally invasive neurosurgical technologies positions it favorably in a growing market. The company's robust clinical evidence and innovative technology provide a competitive edge over traditional surgical methods and other minimally invasive solutions.

Strategic Opportunities and Future Directions